Onco Therapies Limited (OTL), the joint venture between Strides Arcolab Limited and South Africa's Aspen Pharmacare Holdings Limited, has informed that it has accomplished a licensing and supply agreement with GlaxoSmithKline (GSK), the world's second largest drugmaker.

The licensing and supply agreement is for 95 emerging markets, excluding Sub-Saharan Africa and India.

Under the deal, OTL will license intellectual property and supply finished dosage form pharmaceuticals to GSK. OTL will recover intellectual property development costs from GSK in addition to sharing profits from the commercialization of the products.

The first of the products is expected to be launched in 2010.

Earlier, GlaxoSmithKline (GSK) announced that it had signed a licensing collaboration agreement with Aspen and Strides.